EphA2-redirected CAR T-cells

EphA2-redirected CAR T-cells are a form of autologous cell therapy in which a patient's own T lymphocytes are genetically engineered to express a chimeric antigen receptor (CAR) that specifically recognizes the tumor-associated antigen ephrin type-A receptor 2 (EphA2). This approach is designed to direct the immune system to target and destroy cancer cells overexpressing EphA2. The therapy has been investigated primarily for glioblastoma and non-small cell lung cancer (NSCLC), where preclinical and early clinical studies have demonstrated antitumor activity. In first-in-human trials for recurrent glioblastoma, intravenous infusion of these modified T cells showed preliminary tolerability with transient clinical efficacy[1][7]. Preclinical models also support their use in NSCLC with high EphA2 expression[2]. The mechanism involves direct cytotoxicity against tumor cells expressing the target antigen via recognition by the engineered receptor.

Other names

chimeric antigen receptor T cells targeting EphA2anti-EphA2 CAR-Tanti-EphA-2 CAR-Tanti-EphA 2 CAR-TEphA2-targeted CAR-TEphA-2-targeted CAR-TEphA 2-targeted CAR-T